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Abstract  Sildenaﬁl  has  proven  to  efﬁciently  reduce  the  increase  in  pulmonary  artery  pres-
sure provoked  by  hypoxic  pulmonary  vasoconstriction.  However,  its  role  as  a  possible  factor  in
increasing  exercise  performance  under  hypoxic  conditions  remains  to  be  demonstrated.  The
use of  sildenaﬁl  has  increased  among  mountaineers,  not  as  a  high  altitude  pulmonary  edema
preventive  drug,  but  as  a  means  that  could  help  to  improve  performance.  Several  studies  have
attempted to  address  this  issue,  with  conﬂicting  results.  Currently,  despite  the  inconclusive
data at  simulated  or  real  altitude,  and  with  the  clear  evidence  that,  in  normoxia,  sildenaﬁl
does not  improve  performance,  this  drug  is  being  used  (and  sometimes  overused)  by  people
who climb  high  peaks.  However,  such  potential  performance  improvement  would  depend  on
the degree  of  hypoxemia  (altitude)  and  the  individual  responsiveness  to  this  drug.  This  paper
reviews the  current  knowledge  on  this  matter.
© 2015  Consell  Català  de  l’Esport.  Generalitat  de  Catalunya.  Published  by  Elsevier  España,
S.L.U. All  rights  reserved.
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Resumen  Sildenaﬁlo  ha  demostrado  eﬁcacia  reduciendo  la  hipertensión  pulmonar  provocada
por la  vasoconstricción  pulmonar  hipóxica.  Su  papel  como  posible  factor  para  aumentar  el
o  en  condiciones  de  hipoxia  está  por  demostrar,  pero  el  uso  de
ntre  los  montan˜eros,  no  como  un  fármaco  preventivo  del  edema
ino  en  la  creencia  de  que  podría  ayudar  a  mejorar  el  rendimiento
ca.  Varios  estudios  han  tratado  de  abordar  este  tema,  con  resultadosHipoxia;
Normobárico;
Hipobárico
rendimiento  en  el  ejercici
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contradictorios.  Actualmente,  a  pesar  de  que  no  hay  datos  concluyentes,  ni  en  altitud  simulada
ni real,  y  con  la  clara  evidencia  de  que  en  normoxia  el  sildenaﬁlo  no  mejora  el  rendimiento
físico, se  continúa  utilizando  esta  sustancia  (a  veces  en  exceso)  por  personas  que  suben  a  altas
cumbres. Tal  potencial  mejora  de  rendimiento  dependería  del  grado  de  hipoxemia  (altitud)
y de  la  capacidad  de  respuesta  individual  a  este  medicamento.  El  presente  artículo  revisa  el
conocimiento  actual  sobre  este  tema.
© 2015  Consell  Català  de  l’Esport.  Generalitat  de  Catalunya.  Publicado  por  Elsevier  España,
S.L.U. Todos  los  derechos  reservados.
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ince  the  work  of  Ghofrani  et  al.1 about  the  improvement
f  physical  capacity  during  exercise  in  hypoxia  conditions
ue  to  the  use  of  sildenaﬁl,1 several  studies  have  attempted
o  reproduce  their  ﬁndings.  However,  to  date,  there  is  still
ontroversy  over  whether  phosphodiesterase  type  5  (PDE-5)
nhibitor  is  a  substance  that  can  actually  improve  perfor-
ance  under  hypoxic  conditions.  Sildenaﬁl  has  been  used
o  treat  erectile  dysfunction2 through  inhibition  of  PDE-
 activity  which,  in  turn,  increases  the  cyclic  guanosine
onophosphate  (cGMP)  local  concentration,  thus  causing
asodilatation  by  inducing  relaxation  of  arterial  wall  smooth
uscle  ﬁbers,  especially  in  the  corpus  cavernosum  and
ungs.3 In  the  lungs,  its  effect  is  focused  on  the  treatment
f  pulmonary  arterial  hypertension  (PAH)4,5 caused  by  the
eneral  hypoxic  vasoconstriction:  the  vasodilation  response
nduced  by  sildenaﬁl  decreases  pulmonary  vascular  resis-
ance,  thus  favoring  the  uptake  of  oxygen  and  increasing
he  arterial  oxygen  content  (CaO2).  Sildenaﬁl  has  also  been
sed  in  patients  suffering  from  diseases  associated  with
AH  such  as  chronic  heart  failure,6,7 chronic  obstructive
ulmonary  disease  or  idiopathic  pulmonary  ﬁbrosis.8--10 In
ll  these  cases,  sildenaﬁl  was  able  to  decrease  pulmonary
rtery  pressure  (PAP)  and  improve  the  patients  exercise
erformance.
Apart  from  these  medical  considerations,  the  effect  of
ildenaﬁl  in  PAH  and  hypoxic  pulmonary  vasoconstriction
PHV)  in  situations  of  moderate  or  severe  hypoxia  in  healthy
eople  has  also  attracted  researchers’  interest.  The  acute
xposure  to  normobaric  or  hypobaric  hypoxia  produces  a
ulmonary  vasoconstriction  due  to  the  decrease  in  alveolar
xygen  tension  (PAO2),  thus  causing  a  reduction  in  oxy-
en  diffusion  from  alveoli  to  capillaries  and  a  consequent
ecrease  in  the  oxygen  transport  to  other  tissues.11 More-
ver,  increased  pulmonary  artery  pressure  causes  overload
n  the  right  ventricle,  affecting  afterload  and  cardiac  output
CO).12,13
ypoxia and exercise
xposure  to  acute  hypoxia  (AH)  causes  the  reduction  of  the
aximum  aerobic  capacity,  directly  affecting  the  exercise
erformance.14--16 VO2max tends  to  diminish  in  direct  pro-
ortion  to  the  decrease  in  CaO2,  which  occurs  as  hypoxia
ncreases.17,18 Exercise  exacerbates  CaO2 reduction  due  to
U
u
o
The  lower  uptake  of  O2 during  gas  exchanging  in  the  lungs,1,19
hich  may  increase  the  risk  of  pulmonary  edema,11,20 espe-
ially  in  people  predisposed  to  suffer  this  complications
ssociated  to  rapid  ascent.21 Considering  that  the  increase
n  PAP  could  be  an  important  factor  limiting  performance
uring  exercise  in  hypoxia,22 sildenaﬁl  has  been  proposed  as
 potential  ergogenic  aid  for  physical  activity  in  hypoxic  con-
itions  due  to  its  possible  beneﬁts  for  athletic  performance,
nd  has  been  widely  used.23--27 This  could  be  of  especial
nterest  in  some  countries,  such  as  Andean  or  central  Asia
lateaus,  where  many  professional  athletes  and  football  and
ther  collective  sport  teams  have  to  perform  or  play  in  loca-
ions  higher  than  2500  m.  Finally,  sildenaﬁl  use  has  also  been
romoted  under  the  name  of  ‘‘Vitamin  V’’  in  some  Internet
orums  because  it  supposedly  improves  muscle  hypertrophy
n  bodybuilders  and  ﬁtness  enthusiasts.28
ildenaﬁl effects during exercise and hypoxia
esearch  conducted  on  healthy  people,  combining  the
ffects  of  exercise  and  hypoxia  after  sildenaﬁl  administra-
ion,  has  yielded  contrasting  results.  Studies  on  this  subject
resent  a  wide  range  of  designs  and  methodologies  leaving
any  questions  still  unanswered  about  the  possible  bene-
ts  of  the  sildenaﬁl  administration  under  hypoxic  conditions.
he  following  paragraphs  present  a  review  of  the  most  rel-
vant  studies  on  sildenaﬁl  administration  and  exercise  in
ypoxia.  All  the  studies  had  a randomized  double  blind,
lacebo  controlled  and  crossover  design,  except  for  Olfert
t  al.,15 which  was  single-blind  designed  and  did  not  use
lacebo.  Table  1  summarizes  the  main  methodological  char-
cteristics  of  the  included  studies.
The  ﬁrst  published  study  concerning  the  relationship
etween  sildenaﬁl,  exercise  and  hypoxia  was  that  of
hofrani  et  al.1 These  authors  studied  a  group  of  14  people
12  men  and  2  women)  who  had  previous  experience  in  alti-
ude  exposure.  Data  from  the  participants  were  recorded
t  rest  and  during  maximum  incremental  exercise  tests
Wpeak)  in  two  different  situations:  (1)  at  an  altitude  of
71  m  breathing  through  a  mask  of  a  hypoxic  gas  mixture
ith  10%  fraction  of  oxygen  for  2  h and  (2)  at  an  altitude
f  5245  m  after  8  days  of  ascent  until  Everest  base  camp.
nder  a  random-controlled  environment  and  2  h  before  eval-
ating  the  participants,  one  dose  of  50  mg  of  sildenaﬁl  or
ne  dose  of  placebo  were  administered  to  each  group.
heir  results  showed  that  sildenaﬁl  reduced  the  PAH  at
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Table  1  Summary  of  the  main  methodological  aspects  of  studies  about  the  effects  of  sildenaﬁl  in  hypoxic  conditions.
Report  Subjects  Hypoxia
exposure
Hypoxia
type
Sildenaﬁl
dosage
Exercise
intensity
Ghofrani
et  al.  (2004)
12  m  +  2  w
Trained
2  h  10%  O2 [NH]  50  mg  1  h
before  test
Wpeak
Ghofrani
et  al.  (2004)
14  m
Trained
6  days  5400  m  --  HH  50  mg
1 hr  before
test
Wpeak
Richalet
et  al.  (2005)
12  m
Moderately
Trained
6  days  SL  vs  4350  m  --  HH  40  mg
3 times  at
day
VO2max SL
(pre)//VO2max HH
at day  2,
5//VO2max SL
(post)
Ricart et  al.
(2005)
14  m
Untrained
90  min  5000  m  --  HH  100  mg
45 min
before  test
50%  of  theoretical
VO2max by  5  min  at
SL  and  HH
Hsu et  al.
(2006)
10  m
Trained
90  min  12.8%
O2 =  (3900  m)  [NH]
50/100  mg
1 h  before
test
Wpeak SL  +  55%  of
Wpeak 60  min
SL  +  10  TT//Wpeak
NH  +  55%  30  min
NH  +  6  TT
Faoro et  al.
(2007)
8  m  +  6  w
Untrained
1  h  11%  O2 =  (5000  m)
[NH]
vs  10  days  at
5000  m  [HH]
50  mg
30  min
before  test
Wpeak
Kressler
et  al.  (2011)
11  m  +  10  w
Trained
1  h  16.2%
O2 =  (2100  m)  vs
11% O2 =  (5000  m)
[NH]
12.8%
O2 =  (3900  m)  vs
11% O2 =  (5000  m)
[NH]
50  mg
1 h  before
test
Wpeak and  55%
Wpeak by
30 min  +  15  km  (SL
vs NH)
Jacobs
et al.  (2011)
20  m  +  15  w
Trained
60  min  12.8%
O2 =  (3900  m)  vs
11% O2 =  (5000  m)
[NH]
50  mg
1 h  before
test
Wpeak and  55%
Wpeak (alt.  sp.)  by
30 min  +  6  km  (SL
vs NH)
Olfert et  al.
(2011)
8  m  +  8  w
Trained
90  min  11%  O2 =  (5000  m)
[NH]
50  mg
1 h  before
test
(Wpeak)  and  15%,
45%  and  90%  of
VO2max
Toro  et  al.
(2015)
4  m  +  4  w  90  min  4000  m  --  HH  50  mg
1 h  before
test
Wpeak and  60%  of
Wpeak by  6  min  at
SL  and  HH
HH =
t
a
4
2
m
d
m
a
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rest  and  during  exercise.  After  sildenaﬁl  administration,  the
oxygen  saturation  (SaO2)  was  improved  in  acute  induced
(normobaric)  hypoxia  but  not  in  the  natural  high  altitude
(hypobaric)  hypoxia  conditions.  CO  increased  under  both
hypoxic  conditions,  whilst  the  systemic  blood  pressures  were
not  affected  by  sildenaﬁl.  Wpeak improved  by  32%  in  normo-
baric  hypoxia  and  by  11%  in  hypobaric  hypoxia.  The  main
conclusion  of  the  study  was  that  sildenaﬁl  reduced  hypoxic
pulmonary  hypertension  at  rest  and  during  exercise,  most
likely  due  to  the  reduction  in  right  ventricular  afterload,
thus  keeping  an  adequate  gas  exchange  and  systemic  arte-
rial  pressure  and  increasing  exercise  capacity  during  severe
hypoxia.
S
f
t
f hypobaric hypoxia; SL = sea level; Wpeak = maximum workload;
Richalet  et  al.29 exposed  12  healthy  men  (not  acclimated
o  altitude  with  a  moderate  physical  condition)  for  6  days  at
n  altitude  of  4350  m.  The  treatment  was  to  take  one  dose  of
0  mg  of  sildenaﬁl  or  placebo,  three  times  a  day  (8:00  am;
:00  pm  and  8:00  pm).  Measurements  of  systemic  and  pul-
onary  blood  pressure,  CO  and  SaO2, were  taken  during  12
ays,  3  times  a  day.  Days  1-3  were  taken  at  sea  level  (SL),
easurements  of  days  5-10  were  taken  at  high  altitude  (HA),
nd  day  12  was  taken  at  SL  once  again,  after  exposure  to  HA.
everal  Wpeak tests  were  performed.  Two  of  them  were  per-
ormed  at  SL,  one  pre-ascent  and  the  other  post-ascent  and  2
ests  every  3  days  at  altitude.  In  hypoxia,  VO2max decreased
rom  29  to  25%  after  administration  of  sildenaﬁl  and  from
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9  to  35%  with  placebo,  but  in  the  second  test  performed  at
ltitude,  VO2max was  higher  than  the  ﬁrst  test  due  to  acclima-
ization.  After  sildenaﬁl  administration,  PHV  decreased  and
aO2 was  signiﬁcantly  higher  compared  to  placebo  at  alti-
ude.  Systemic  blood  pressure  and  CO  were  not  modiﬁed  by
ildenaﬁl.  It  was  concluded  that  sildenaﬁl  protects  against
he  development  of  pulmonary  hypertension  induced  by  alti-
ude,  improving  gas  exchange,  limiting  the  altitude-induced
ypoxemia  and  decreasing  exercise  performance,  and  did
ot  alter  normal  physiological  processes  of  acclimatization.
n  hypoxia,  VO2max decreased  from  29  to  25%  after  silden-
ﬁl  administration  and  from  39--35%  with  placebo,  but  the
econd  test  performed  at  altitude,  VO2max was  higher  than
he  ﬁrst  test  due  to  acclimatization.  After  sildenaﬁl  admin-
stration,  PHV  decreased  and  SaO2 was  signiﬁcantly  higher
ompared  to  placebo  at  altitude.  Systemic  blood  pressure
nd  CO  were  not  modiﬁed  by  sildenaﬁl.  The  main  conclu-
ion  was  that  sildenaﬁl  protected  against  the  development
f  pulmonary  hypertension  induced  by  altitude,  improving
as  exchange,  limiting  the  altitude-induced  hypoxemia  and
ecreasing  exercise  performance,  and  did  not  alter  normal
hysiological  processes  of  acclimatization.
Ricart  et  al.30 showed  data  of  two  Wpeak tests  (5  min,  50%
f  VO2max)  performed  in  non-consecutive  days  under  both
ormoxia  and  hypobaric  hypoxia  (1  h  at  a  simulated  alti-
ude  of  5000  m)  conditions.  Their  study  involved  14  healthy
en  without  HA  experience  to  whom  100  mg  of  sildena-
l  or  placebo  were  administered  45  min  before  each  test.
ildenaﬁl  reduced  the  PAP  at  rest  and  during  exercise  in
ypoxia  whilst  in  normoxia  were  no  changes  associated
ith  the  drug.  SaO2 remained  unchanged  during  normoxia
nd  hypoxia  at  rest,  but  in  hypoxia  during  exercise  SaO2
ncreased  slightly.  Heart  rate  (HR)  showed  a  minor  rise
ith  sildenaﬁl  during  rest  in  normoxia  and  hypoxia,  dur-
ng  exercise  increased  in  normoxia,  but  in  hypoxia  did  not
hange.  The  main  conclusions  of  the  study  were  that  sil-
enaﬁl  decreases  pulmonary  hypertension  induced  by  acute
xposure  to  hypoxia  and  may  be  useful  for  the  modulation  of
AP.  It  should  be  noted  that  exercise  during  exposure  to  sim-
lated  hypobaric  hypoxia  was  intense  but  very  short  (5  min).
AP  was  measured  a  few  minutes  of  arrival  of  simulated  alti-
ude,  and  probably  maximal  PAP  was  not  reached  and  could
e  underestimated.
Hsu  et  al.18 reported  data  on  10  trained  men,  cyclists
nd  triathletes,  who  performed  a  peak  work  capacity  test
Wpeak)  at  SL  followed  by  four  exercise  tests  (1  practice,  3
xperimental).  The  same  procedure  was  used  during  hypoxic
as  breathing  (12.8%  oxygen;  equivalent  to  3874  m)  to  simu-
ate  HA.  All  exercise  tests  were  interspersed  at  least  3  days.
lacebo  or  100  mg  of  sildenaﬁl  were  administered  at  random
uring  the  experimental  tests.  The  tests  were  performed  in
ormoxia  to  55%  of  Wpeak for  60  min,  5  min  break  and  one
ime-trial  test  of  10  km.  In  HA  the  test  was  performed  to
5%  of  Wpeak for  30  min,  5  min  break  and  one  time-trial  test
f  6  km.  In  SL,  the  parameters  evaluated  at  rest  and  exer-
ise  were  not  modiﬁed  by  any  dose  of  sildenaﬁl,  nor  during
f  effort  tests.  In  HA,  during  exercise  at  55%  Wpeak, silden-
ﬁl  increased  SaO2 by  approximately  5%;  CO  increased  by
bout  20%,  stroke  volume  (SV)  increased  around  17%  and
ystolic  blood  pressure  decreased  in  a  9%.  In  time-trial  test
n  hypoxia  the  results  showed  that  using  sildenaﬁl,  total
ime  was  less  (−15%),  and  that  watts  (16%),  CO  (8.4%)  and
S
c
t
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aO2 (5.4%)  increased  in  comparison  to  placebo.  One  of  the
ost  important  ﬁndings  of  the  investigation  was  that  six
ubjects  experienced  no  improvement  in  the  time-trial  test
n  hypoxia  after  sildenaﬁl  administration,  whilst  four  sub-
ects  showed  a  good  response  to  sildenaﬁl  administration
ince  they  increased  the  time  duration  in  39%.  Responders
lso  showed  increases  in  CO  by  25%  at  rest  and  32%  during
xercise  (55%  Wpeak)  in  HA.  Another  remarkable  data  was
hat  SV  in  exercise  at  55%  Wpeak after  placebo  administra-
ion  led  to  a  greater  drop  in  responders  (26%)  than  in  no
esponders  (2.3%),  from  SL  to  HA,  thus  suggesting  a  strong
elationship  between  the  higher  values  of  SV  obtained  by
esponders  in  exercise  at  SL  and  the  decrement  suffered
uring  HA.  Because  PAH  was  not  determined,  it  was  not
ossible  to  verify  if  the  responders  could  have  had  greater
AH  and  a  consequent  reduced  cardiac  ﬁlling  which  could
xplain  their  good  response  to  sildenaﬁl  treatment.  The
ain  conclusion  was  that  in  acute  hypoxia,  sildenaﬁl  might
mprove  cardiovascular  function,  SaO2 and  performance  only
n  some  individuals  (responders)  and  also  that  positive  sil-
enaﬁl  responders  could  potentially  be  identiﬁed  by  their
V  reduction  upon  acute  hypoxic  exposure.
Faoro  et  al.14 evaluated  the  effect  of  the  administra-
ion  of  a  50  mg  dose  of  sildenaﬁl  in  14  healthy  subjects
6  women  and  8  men)  not  acclimatized  to  the  altitude.
easurements  were  performed  in  normoxia,  acute  normo-
aric  hypoxia  (10%  FiO2,  equivalent  to  5500  m)  and  after
wo  weeks  of  acclimatization  to  5000  m  in  the  Mount  Chim-
orazo  deﬁned  as  chronic  hypoxia  (CH).  At  rest,  sildenaﬁl
ncreased  HR  and  CO,  whereas  pulmonary  vascular  resis-
ance  (PVR)  decreased  both  in  normoxia,  AH  and  CH.  Mean
ulmonary  arterial  pressure  also  decreased  in  AH  and  CH
lthough  systolic  pulmonary  arterial  pressure  decreased  only
n  AH.  During  exercise  in  AH,  sildenaﬁl  increased  VO2max,  O2
ulse,  HR  and  SaO2.  In  CH,  sildenaﬁl  increased  VO2max and
2 pulse.  Their  conclusion  was  that  sildenaﬁl  could  increase
xercise  capacity  in  acute  normobaric  hypoxia  due  to  an
mprovement  in  arterial  oxygenation,  rather  than  a  hemo-
ynamic  effect.  In  spite  of  sildenaﬁl  increased  VO2max and
aO2 in  AH,  it  was  not  able  to  improve  maximum  workload
r  maximum  respiratory  exchange  ratio.
Kressler  et  al.31 studied  21  trained  cyclists  and  triath-
etes  (11  men  and  10  women).  To  determine  the  individual
erformance  capacity,  all  subjects  performed  three  Wpeak
est,  one  at  SL  and  two  at  normobaric  HA.  After  random
dministration  of  50  mg  of  sildenaﬁl  or  placebo,  2  tests  were
erformed  at  normobaric  HA  (3900  m;  equivalent  to  12.8%
iO2) and  2  were  performed  at  normobaric  moderate  alti-
ude  (2100  m;  equivalent  to  16.2%  FiO2).  Every  experimental
est  consisted  in  30  min  at  55%  of  altitude-speciﬁc  Wpeak fol-
owed  by  15  km  time-trial  test.  Sildenaﬁl  did  not  signiﬁcantly
ffect  the  Wpeak, HR,  SV,  CO  nor  SaO2 in  comparison  with
lacebo  in  HA.  In  the  experimental  tests  at  55%  of  Wpeak after
ildenaﬁl  administration  at  moderate  altitude,  HR  and  CO
ere  higher  than  placebo.  In  the  time-trial  test,  sildenaﬁl
id  not  improve  time-trial  performance.  In  fact,  sildenaﬁl  at
oderate  altitude  signiﬁcantly  reduced  the  average-power
−4%)  and  also  the  speed  test  (−2%)  compared  to  placebo.
ildenaﬁl  signiﬁcantly  increased  SaO2 values  at  HA  (3%).  The
onclusions  were  that  sildenaﬁl  had  little  or  no  inﬂuence  on
he  supply  of  oxygen  at  rest  or  during  exercise  since  it  did
ot  improve  the  SaO2, CO,  Wpeak nor  time-trial  performance
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in  men  and  women  neither  at  moderate  or  high  altitude.
These  authors  concluded  that  the  magnitude  of  sildenaﬁl
effects  could  be  determined  by  the  geographical  altitude
and  the  subsequent  degree  of  hypoxia,  thus  proposing  that
the  potential  beneﬁcial  effects  of  sildenaﬁl  during  exercise
are  unlikely  to  be  obtained  at  altitudes  less  than  4000  m.
Jacobs  et  al.32 studied  35  trained  subjects  (20  men  and  15
women,  cyclists  and  triathletes)  that  performed  a  Wpeak test
at  SL  and  another  in  simulated  HA  (12.8%  FiO2 or  3900  m).
Later,  they  performed  three  experimental  exercise  tests
(30  min  at  55%  of  altitude-speciﬁc  capacity  +  6  km  time-trial)
one  at  SL  and  two  experimental  exercise  tests  at  simulated
HA  after  ingestion  of  either  placebo  or  50  mg  sildenaﬁl  with
at  least  48  h  between  the  tests.  Sildenaﬁl  administration  did
not  signiﬁcantly  affect  any  cardiovascular  and  hemodynamic
variables  at  rest  or  during  exercise  nor  improved  perfor-
mance  and  power  output  in  most  men  or  women  compared  to
placebo.  However,  sildenaﬁl  resulted  in  signiﬁcantly  higher
SaO2 values  in  women  during  exercise  at  HA  compared  to
placebo.  The  efﬁcacy  of  sildenaﬁl  during  exercise  in  hypoxic
conditions  seemed  related  to  the  ability  to  increase  the  sup-
ply  of  oxygen  and  the  subsequent  effects  depend  on  the
intensity  of  hypoxia  and  individual  susceptibility  to  PHV.  May
be  a  very  small  percentage  of  endurance-trained  men  and
women  could  have  relevant  improvements  in  aerobic  perfor-
mance  after  sildenaﬁl  administration  at  a  simulated  altitude
of  3900  m.
Olfert  et  al.15 compared  the  effect  of  sildenaﬁl  and
bosentan  in  16  athletes  (8  men  and  8  women).  Each  sub-
ject  performed  two  tests  of  VO2max with  two  days  maximum
time  elapsed:  one  day  on  normoxia  and  another  in  normo-
baric  hypoxia  (0.11%  FiO2;  equivalent  to  5000  m).  A  week
later,  subjects  performed  a  progressive  submaximal  test
with  intensities  of  15%  (light),  45%  (moderate)  and  90%
(heavy)  of  VO2max in  hypoxia.  The  duration  of  exercise  in
each  intensity  was  5  min  with  the  exception  of  the  last  inten-
sity,  which  depended  on  individual  capacity  to  complete  the
programmed  workload.  Subjects  received  only  one  type  of
treatment  without  informing  which  drug  was  administered
(placebo  was  not  used).  The  same  exercise  was  performed
before  and  1  h  after  taking  a  single  dose  of  sildenaﬁl  (50  mg)
or  bosentan  (62.5  mg)  on  the  same  day.  Both  drugs  caused
a  small  but  signiﬁcant  increase  in  partial  pressure  of  oxy-
gen  in  arterial  blood  (PaO2)  and  SaO2 (3--4%)  at  rest  and
during  exercise  in  hypoxia,  both  in  men  and  in  women.  On
the  other  hand,  carbon  dioxide  partial  pressure  in  arte-
rial  blood  (PaCO2)  decreased  but  only  when  sildenaﬁl  was
administered.  There  were  no  signiﬁcant  changes  in  ventila-
tion  or  in  other  arterial  parameters.  HR  at  rest  and  during
exercise  signiﬁcantly  increased  after  the  administration  of
both  sildenaﬁl  and  bosentan  in  all  subjects.  Gender-related
effects  were  evident  in  women  which  showed  higher  PaO2
and  SaO2 as  compared  to  men  during  exercise  after  both
drugs  administration.  So,  sildenaﬁl  and  bosentan  were  able
to  improve  pulmonary  gas  exchange  in  healthy  men  and
women  in  hypoxia.  However,  it  was  not  possible  to  assess  if
the  slight  improvements  in  arterial  oxygenation  (PaO2) cor-
responded  to  better  physical  performance  in  hypoxia.  The
possibility  that  during  hypoxic  exercise  such  improvement
in  PaO2 could  be  physiologically  relevant  is  suggestive,  but
the  evidence  of  enhanced  exercise  capacity  performance  in
healthy  people  using  sildenaﬁl  remains  elusive.
f
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Our  workgroup  performed  a double-blind  crossover  study
o  determine  the  effects  of  sildenaﬁl  on  cardiovascular,
espiratory  and  metabolic  parameters  in  normoxia  and  dur-
ng  acute  exposure  to  hypobaric  hypoxia  (4000  m)  at  rest
nd  during  maximal  and  submaximal  (60%  VO2max)  exercise
ests  in  11  volunteers  non-acclimatized  to  altitude.  One
our  before  testing  started,  sildenaﬁl  (100  mg)  or  a  placebo
as  orally  administered.  The  ﬁrst  phase  (maximal  incre-
ental  test)  started  from  20  W,  and  20  W  were  added  per
inute  until  exhaustion.  The  second  phase  was  a  submax-
mal  intensity  test,  which  lasted  for  6  min  at  60%  of  the
aximum  workload  reached  in  the  ﬁrst  phase.  The  break
etween  each  of  the  two  phases  was  about  30  min,  until
asal  heart  rate  was  recovered.  We  concluded  that  in  nor-
oxic  conditions,  sildenaﬁl  did  not  affected  performance.
imilarly,  no  signiﬁcant  differences  were  found  in  cardio-
ascular  and  respiratory  parameters  in  hypoxic  conditions
t  rest  or  during  exercise.  The  use  of  sildenaﬁl  to  improve
hysical  performance  in  non-acclimated  subjects  is  not  sup-
orted  by  our  data.33
We  have  included  in  this  review  a  meta-analysis  study  by
u  et  al.34 on  sildenaﬁl  effects  at  HA,  although  data  about
ildenaﬁl  effects  during  exercise  were  not  included.  These
uthors  analyzed  5 articles,  3  of  which  have  already  been
ommented  above.1,14,29 It  was  evident  that  sildenaﬁl  admin-
stration  is  able  to  blunt  the  PAP  increase  induced  by  hypoxia
xposure,  but  it  does  not  improved  SaO2 and  HR.  Moreover,
cute  mountain  sickness  symptoms  were  not  relieved  by  sil-
enaﬁl  treatment.
In summary,  different  cardiovascular,  ventilatory  and
etabolic  parameters  that  were  evaluated  in  several  reports
re  presented  in  Table  2.  Cardiovascular  variables  that
xperimented  more  changes  after  sildenaﬁl  administration
ere  HR,  CO  and  SaO2,  showing  a  certain  tendency  to
ncrease  their  values  in  hypoxia.  However,  data  are  not
ategorical,  both  at  rest  and  during  exercise.  The  arte-
ial  blood  pressure  (systolic,  diastolic  and  mean)1,18,29,31,32
nd  systolic  volume18,31,32 were  almost  not  affected.  Lung
unction  parameters  (ventilation,  tidal  volume,  respira-
ory  rate  and  respiratory  exchange  ratio)  were  unaffected
y  the  drug14,15,18,30.  Finally,  the  exercise  values  such  as
peak
1,14,15,18,29,31,32 or  VO2max14,29 are  not  conclusive  at  all
o  afﬁrm  that  sildenaﬁl  signiﬁcantly  improves  performance
uring  exposure  to  acute  hypoxia,  regardless  its  normobaric
r  hypobaric  nature.
ormobaric versus hypobaric hypoxia
n  important  point  to  keep  in  mind  when  comparing  all  the
ited  reports  it  is  to  consider  the  difference  in  the  hypoxia
onditions  (simulated  or  natural)  and  the  type  of  hypoxia
normobaric  or  hypobaric)  that  subjects  underwent,  because
ome  studies  showed  differences  between  exposition  to  nor-
obaric  and  hypobaric  hypoxia.35--39 Comparing  both  types
f  hypoxia,  one  study  described  that  hypobaric  hypoxia  leads
o  greater  hypoxemia,  hypocapnia,  alkalosis  and  lower  blood
aO2 than  normobaric  conditions.  These  physiological  dif-
erences  could  be  the  result  of  an  increase  in  dead  space
entilation,  probably  related  to  reduced  barometric  pres-
ure  in  hypobaric  hypoxia.38 Another  research  showed  that
ome  variables  of  heart  rate  variability  were  affected  in
32
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Table  2  Summary  changes  reported  by  the  reviewed  studies  in  physiological  parameters  after  sildenaﬁl  administration  v/s  placebo.
Parameters  Ghofrani
et  al.  (2004)
Richalet  al.
(2005)
Ricart  et  al.
(2005)
Hsu  et  al.
(2006)
Faoro  et  al.
(2007)
Kressler
et  al.  (2011)
Jacobs
et  al.  (2011)
Olfert  et  al.
(2011)
Toro  et  al.
(2015)
PAP  (mmHg)  ↓  R,
AHn-HAh
↓ Ex
AHn-HAh
↓,  HAh  ↔  R-Ex;  Nm
↓  R-Ex,  AHh
--  ↓  R,  AHn-CH  --  --  --  --
Wpeak (W)  ↑  Ex,
AHn-HAh
↑,  HAh  --  ↔  Tt,  Nm
↑  Tt,  AHn
↔  Ex,
AHn-CH
↓  Tt  MAn
↔  Tt  AHn
↔  55%,  AHn
↔ Tt,  AHn
↔  AHn  ↔
R-Ex/60%;
Nm-HAh
Sys (mmHg)  ↔  R,
AHn-HAh
↔  Ex,
AHn-HAh
↔, HAh  --  ↔  55%,  Nm
↓55%,  AHn
--  ↔  R;  ↔
55%,
MAn-AHn
↔  R,  55%,
AHn
--  ↔
R-Ex/60%;
Nm-HAh
HR
(beats/min)
↔ R,
AHn-HAh
↑ Ex,  HA
↔  Ex  AHn
↓,  HAh  ↑  R,
Nm-AHh
↑Ex,  Nm
↔  Ex,  AHh
↔  55%  --  Tt,
Nm
↔  55%  --  Tt,
AHn
↑  R,
Nm-AHn-CH
↑Ex,  CH
↔  Ex,  AHn
↑  55%  MAn
↔  AHn
↔  Tt
MAn-AHn
↑  R  (m),
AHn
↔  55%,  AHn
↔ Tt,  AHn
↑  AHn  ↔
R-Ex/60%;
Nm-HAh
SaO2 (%)  ↔  R,
AHn-HAh
↑ Ex,  AHn;
↔  Ex,  HAh
↑,  HAh  ↔  R,
Nm-AHh
↔  Ex,  Nm
↑ Ex,  AHh
↔  55%  --  Tt,
Nm
↑ 55%  --  Tt,
AHn
↔  R,
Nm-AHn-CH
↑  Ex,  AHn
↔  Ex,
Nm-CH
↑  55%  AHn  --
↑Tt  AHn
↔  MAn
↔  R,
MAn-AHn
↑  55%  (w),
AHn
↑  AHn  ↔
R-Ex/60%;
Nm-HAh
CO (L/min)  ↑  R,  AHn;  ↔
R, HAh
↑ Ex
AHn-HAh
↔,  HAh  --  ↔  55%  --  Tt,
Nm
↑ 55%  --  Tt,
AHn
↑  R;  Nm,
AHn-CH
↑  55%  MAn
↔,  AHn
↔  R,  55%,
AHn
--  ↔
R-Ex/60%;
Nm-HAh
Dia (mmHg)  --  ↔, HAh  --  --  --  ↔  R,  55%,
MAn-AHn
↔  R,  55%,
AHn
--  ↔  R-Ex/Nm
↓ 60%;  HAh
VO2max --  ↑,  HAh  --  --  ↑  Ex,  AHn
↔  Ex,  CH
--  --  --  --
RR
(breaths min−1)
--  --  ↔  R-Ex,
Nm-AHh
--  --  --  --  --  ↔
R-Ex/60%;
Nm-HAh
VT (L  min−1)  --  --  ↔  R-Ex,
Nm-AHh
--  --  --  --  --  ↔
R-Ex/60%;
Nm-HAh
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Table  2  (Continued)
Parameters Ghofrani
et  al.  (2004)
Richalet  al.
(2005)
Ricart  et  al.
(2005)
Hsu  et  al.
(2006)
Faoro  et  al.
(2007)
Kressler
et  al.  (2011)
Jacobs
et  al.  (2011)
Olfert  et  al.
(2011)
Toro  et  al.
(2015)
Efr  (%) -- -- ↔  R-Ex,
Nm-AHh
-- -- -- -- -- --
VE (L  min−1) -- -- ↔  R-Ex,
Nm-AHh
-- ↔  Ex,
Nm-AHn-CH
-- -- ↔  AHn ↔
R-Ex/60%;
Nm-HAh
SV
(ml beat−1)
-- -- -- ↔  55%  -- Tt,
Nm
↑ 55%,  AHn
↔  Tt,  AHn
-- ↔  MAn-AHn ↔  R,  55%,
AHn
-- ↔
R-Ex/60%;
Nm-HAh
RPE -- -- -- ↔  55%,
Nm-AHn
-- ↔  R,  55%,
MAn-AHn
↔  55%,  AHn -- --
Tt (min) -- -- -- ↔  55%  -- Tt,
Nm
↓ Tt,  AHn
-- ↑  Tt  MAn;
↔  AHn
↔, Tt,  AHn -- --
RER -- -- -- ↔  55%,  Nm ↔  Ex,
AHn-CH
-- -- ↔  AHn ↔
R-Ex/60%;
Nm-HAh
TAM (mmHg) -- -- -- -- ↔  R,
AHn-CH
-- --  --  ↔
R-Ex/60%;
Nm-HAh
O2 pulse  (ml
beat−1)
-- -- -- -- ↑  Ex,  AHn;
↔  Ex,  CH
-- -- -- ↔
R-Ex/60%;
Nm-HAh
VE/VCO2 (L) -- -- -- -- ↔  Ex,
AHn-CH
-- -- -- ↔
R-Ex/60%;
Nm-HAh
VO2
(L  min−1)
--  --  --  ↔  55%,  Nm  ↔  Ex,
AHn-CH
--  --  ↔  AHn  ↔
R-Ex/60%;
Nm-HAh
Speed
(Km h−1)
--  --  --  --  --  ↓  Tt  MAn;
↔  AHn
--  --  --
VCO2
(L  min−1)
--  --  --  --  --  --  --  ↔  AHn  ↔
R-Ex/60%;
Nm-HAh
Abbreviations and symbols: ↑ = sildenaﬁl increased compared to placebo; ↓ = sildenaﬁl decreased compared to placebo; ↔ = no changes; (--) = not evaluated; AHh = acute hypoxia (hypobaric);
AHn = acute hypoxia (normobaric); CH = chronic hypoxia; CO = cardiac output; Dia = diastolic blood pressure; Efr = ejection fraction; Ex = exercise; Hah = high altitude (hypobaric); HR = heart
rate; (m) = men; Man = moderate hypoxia (normobaric); MAP = mean arterial pressure; Nm = normoxia; O2 Pulse = oxygen pulse; PAP = pulmonary artery pressure; R = rest; RER = respiratory
exchange ratio; RPE = rating of perceived exertion; RR = respiratory rate; SaO2 = arterial oxygen saturation; SV = stroke volume; Sys = systolic blood pressure; Tt = trial time; VE = volume of
expired air; VE/VCO2 = respiratory equivalent for carbon dioxide; VO2 = oxygen consumption; VO2max = maximum oxygen uptake; VCO2 = production of carbon dioxide; VT = tidal volume;
(w) = women; Wpeak = maximal workload; 55% = 55% of VO2max; 60% = 60% of Wpeak obtained in maximal test.
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ypobaric  hypoxia  but  not  in  normobaric  hypoxia.35 How-
ver,  other  factors  such  as  time  of  exposure  to  hypoxia,  the
revious  history  of  acclimatization,  temperature  or  humidity
hould  be  considered  as  possible  causes  of  these  differ-
nces.  Furthermore,  the  small  sample  sizes  in  many  studies
ay  also  limit  the  conclusions  that  can  be  drawn  from  the
esults.39
onclusions
ue  that  initial  research  on  the  effects  of  sildenaﬁl  on
ulmonary  circulation  were  conducted  in  patients  with  car-
iopulmonary  disease,  it  was  possible  to  early  conﬁrm  that
ildenaﬁl  is  an  effective  vasodilator  of  the  pulmonary  arter-
es  also  in  healthy  people,  whether  in  the  hypobaric  hypoxia
r  under  normobaric  conditions.1,14,29,30
However,  it  has  been  ruled  out  any  performance
mprovement  under  normoxic  conditions  after  sildenaﬁl
dministration.  Those,  the  use  of  sildenaﬁl  as  an  ergogenic
ubstance  under  normoxic  conditions,  or  combining  silden-
ﬁl  with  anabolic  steroids  to  achieve  a  better  oxygenation
f  the  muscle  ﬁbers  to  elicit  their  hypertrophy  lacks  of  sci-
ntiﬁc  evidence.
Considering  the  current  ambiguity  regarding  the  real  abil-
ty  of  sildenaﬁl  to  improve  athletic  performance,  studies
oncur  that  the  effectiveness  of  sildenaﬁl  during  exercise
t  altitude  is  related  to  its  ability  to  improve  the  oxygen
upply  to  increase  SaO2 and/or  cardiac  output.  The  mag-
itude  of  these  effects  appears  to  be  determined  by  the
everity  of  hypoxemia  and  hypoxia  and  the  individual
usceptibility  to  hypoxic  pulmonary  vasoconstriction  and
ndividual  response  to  the  drug’s  effect.
Based  on  present  data,  it  seems  unlikely  that  sildena-
l  may  exert  beneﬁcial  effects  in  oxygen  delivery  or  CaO2
uring  intense  exercise  at  altitudes  less  than  4000  m.  Consid-
ring  that,  except  for  climbers,  no  other  sport  is  practiced
t  this  altitude,  the  use  of  sildenaﬁl  as  an  ergogenic  aid  does
eems  ineffective.  On  the  contrary,  possible  adverse  effects
ay  be  caused  by  this  drug,  such  as  headaches,  hypotension
r  other  cardiovascular  and  hemodynamic  unbalances.
More  research  on  the  effects  of  sildenaﬁl  or  other  PDE-5
nhibitors  (tadalaﬁl  or  vardenaﬁl)  at  altitude  still  have  to  be
lariﬁed.  The  dosage  of  the  drug,  the  degree  of  acclimatiza-
ion  of  the  subjects  and  the  exercise  intensity  are  variables
hat  must  be  controlled  in  order  to  evaluate  the  real  bene-
cial  effects  on  exercise  performance  during  acute  hypoxia
xposure.
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